An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics

Dulaglutide (dula, LY2189265) is a once-weekly glucagon-like peptide-1 analog in development for the treatment of type 2 diabetes mellitus. An adaptive, dose-finding, inferentially seamless phase 2/3 study was designed to support the development of this novel diabetes therapeutic. The study is divid...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Geiger, Mary Jane, Skrivanek, Zachary, Gaydos, Brenda, Chien, Jenny, Berry, Scott, Berry, Donald, Anderson, James H.
Médium: Artigo
Jazyk:Inglês
Vydáno: Diabetes Technology Society 2012
Témata:
Symposium
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570871/
https://ncbi.nlm.nih.gov/pubmed/23294776
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky